ValuEngine lowered shares of Retrophin (NASDAQ:RTRX) from a buy rating to a hold rating in a research note published on Thursday, ValuEngine reports.

Several other research analysts also recently weighed in on RTRX. BidaskClub downgraded shares of Retrophin from a buy rating to a hold rating in a research note on Friday, January 11th. TheStreet downgraded shares of Retrophin from a c- rating to a d+ rating in a research note on Friday, February 22nd. Zacks Investment Research upgraded shares of Retrophin from a strong sell rating to a hold rating in a research note on Wednesday, February 27th. Finally, Svb Leerink restated an outperform rating on shares of Retrophin in a research note on Tuesday, February 26th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus target price of $50.50.

Shares of RTRX stock opened at $20.05 on Thursday. The firm has a market capitalization of $830.81 million, a PE ratio of -7.89 and a beta of 1.02. The company has a quick ratio of 4.68, a current ratio of 4.74 and a debt-to-equity ratio of 0.61. Retrophin has a twelve month low of $19.57 and a twelve month high of $33.00.

Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.63) by $0.42. The business had revenue of $43.77 million during the quarter, compared to the consensus estimate of $43.54 million. Retrophin had a negative net margin of 62.51% and a negative return on equity of 33.53%. The business’s quarterly revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.07 earnings per share. On average, research analysts predict that Retrophin will post -2.47 EPS for the current year.

In other Retrophin news, SVP William E. Rote sold 1,250 shares of the stock in a transaction on Friday, February 15th. The shares were sold at an average price of $21.44, for a total transaction of $26,800.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Laura Clague sold 2,033 shares of the stock in a transaction on Tuesday, February 12th. The shares were sold at an average price of $21.44, for a total transaction of $43,587.52. Following the transaction, the chief financial officer now owns 11,016 shares in the company, valued at $236,183.04. The disclosure for this sale can be found here. Insiders sold 12,917 shares of company stock valued at $277,140 over the last 90 days. Insiders own 3.67% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of RTRX. Wells Fargo & Company MN boosted its stake in Retrophin by 16.1% during the 3rd quarter. Wells Fargo & Company MN now owns 110,585 shares of the biopharmaceutical company’s stock valued at $3,177,000 after acquiring an additional 15,335 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Retrophin by 17.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,087,025 shares of the biopharmaceutical company’s stock valued at $31,229,000 after acquiring an additional 164,982 shares during the last quarter. GSA Capital Partners LLP bought a new position in Retrophin during the 3rd quarter valued at $333,000. Jane Street Group LLC bought a new position in Retrophin during the 3rd quarter valued at $2,296,000. Finally, Man Group plc boosted its stake in Retrophin by 19.0% during the 3rd quarter. Man Group plc now owns 71,742 shares of the biopharmaceutical company’s stock valued at $2,061,000 after acquiring an additional 11,455 shares during the last quarter.

Retrophin Company Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

See Also: What is the QQQ ETF?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.